Skip to main content
. Author manuscript; available in PMC: 2024 Feb 13.
Published in final edited form as: Cancer Cell. 2023 Jan 26;41(2):356–372.e10. doi: 10.1016/j.ccell.2023.01.002

Figure 8: Proposed mechanism of neutrophil-dependent tumor eradication.

Figure 8:

Treatment with neutrophil-activating therapy recruits neutrophils to the tumor through TNFR1 signaling and activates the complement AP, generating C5a. C5a signals through C5AR1 in neutrophils and induces neutrophil activation and production of LTB4, which drives XO activity in the tumor environment. ROS produced by XO induce oxidative damage and death in tumor cells, driving tumor clearance. Tumor-binding antibody contributes to neutrophil killing of tumor cells by inducing ADCC, possibly involving trogocytosis. While not dependent on adaptive immunity, this process is capable of priming protective immune memory.